Market Research Logo

Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2015

Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2015’, provides an overview of the Pseudomonas Aeruginosa Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pseudomonas Aeruginosa Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pseudomonas Aeruginosa Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pseudomonas Aeruginosa Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pseudomonas Aeruginosa Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pseudomonas Aeruginosa Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pseudomonas Aeruginosa Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Pseudomonas Aeruginosa Infections Overview
Therapeutics Development
Pipeline Products for Pseudomonas Aeruginosa Infections - Overview
Pipeline Products for Pseudomonas Aeruginosa Infections - Comparative Analysis
Pseudomonas Aeruginosa Infections - Therapeutics under Development by Companies
Pseudomonas Aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes
Pseudomonas Aeruginosa Infections - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Pseudomonas Aeruginosa Infections - Products under Development by Companies
Pseudomonas Aeruginosa Infections - Products under Investigation by Universities/Institutes
Pseudomonas Aeruginosa Infections - Companies Involved in Therapeutics Development
Achaogen Inc.
Adenium Biotech ApS
Aeolus Pharmaceuticals, Inc.
AlgiPharma AS
AmpliPhi Biosciences Corporation
AnGes MG, Inc.
Arch Biopartners, Inc.
Aridis Pharmaceuticals LLC
Arno Therapeutics, Inc.
AstraZeneca Plc
Biolytics Pharma
CSA Biotechnologies LLC
Evaxion Biotech
F. Hoffmann-La Roche Ltd.
FOB Synthesis, Inc.
GlaxoSmithKline Plc
GlycoMimetics, Inc.
Helix BioMedix, Inc.
Hsiri Therapeutics, LLC
Insmed Incorporated
Lascco SA
LegoChem Biosciences, Inc
Lytix Biopharma AS
MedImmune, LLC
Melinta Therapeutics, Inc
Microbiotix, Inc.
MicuRx Pharmaceuticals, Inc.
Nosopharm SAS
Novabiotics Limited
Novan, Inc.
Omnia Molecular Ltd.
Pfizer Inc.
Pherecydes Pharma SA
Phico Therapeutics Limited
Phylogica Limited
Polyphor Ltd.
Sanofi
Sarepta Therapeutics, Inc.
Sealife PHARMA GMBH
Sequoia Sciences, Inc.
Shionogi & Co., Ltd.
Soligenix, Inc.
Syntiron LLC
Tetraphase Pharmaceuticals Inc.
Trana Discovery, Inc.
Valneva SE
Varinel, Inc.
Vaxdyn, S.L.
Zambon Company S.p.A.
Pseudomonas Aeruginosa Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(fosfomycin + tobramycin) - Drug Profile
AA-139 - Drug Profile
AB-569 - Drug Profile
ABPA-01 - Drug Profile
ACHN-975 Prodrug - Drug Profile
AEOL-20415 - Drug Profile
Aerucin - Drug Profile
AG-30/5C - Drug Profile
AGL-503 - Drug Profile
amikacin sulphate - Drug Profile
Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile
Antisense Oligonucleotide for Drug Resistant Pseudomonas Aeruginosa Infections - Drug Profile
AR-104 - Drug Profile
AR-13 - Drug Profile
Biologic for Pseudomonas Aeruginosa Infection - Drug Profile
CAL-02 - Drug Profile
Cell Therapy for GBM and Pseudomonas Aeruginosa Infections - Drug Profile
Cephalosporin + Beta-Lactamase Inhibitor - Drug Profile
CSA-13 - Drug Profile
dehydroleucodine - Drug Profile
dusquetide - Drug Profile
EBX-001 - Drug Profile
FSI-1671 - Drug Profile
FSI-1686 - Drug Profile
G-10 - Drug Profile
GMI-1051 - Drug Profile
GN snare - Drug Profile
GN-4474 - Drug Profile
HB-1345 - Drug Profile
HT-05 - Drug Profile
KBP-7963 - Drug Profile
LCB-100200 - Drug Profile
LTX-109 - Drug Profile
MBX-2359 - Drug Profile
MBX-2402 - Drug Profile
MDN-0057 - Drug Profile
Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile
MRX-V - Drug Profile
NBTI-5463 - Drug Profile
NOSO-95179 - Drug Profile
NP-432 - Drug Profile
NVN-1000 - Drug Profile
Oligomer G for Pseudomonas Aeruginosa and Candida Infectious - Drug Profile
OM-011818 - Drug Profile
Panaecin - Drug Profile
POL-7080 Follow-On - Drug Profile
PP-1131 - Drug Profile
PP-1231 - Drug Profile
pseudomonas + VAP vaccine - Drug Profile
Pseudomonas aeruginosa vaccine - Drug Profile
Pseudomonas aeruginosa vaccine - Drug Profile
Pseudomonas aeruginosa vaccine - Drug Profile
Pseudomonas aeruginosa vaccine - Drug Profile
pseudomonas vaccine - Drug Profile
PT-3.1 - Drug Profile
PT-3.33 - Drug Profile
Recombinant Protein for Pseudomonas Aeruginosa Infections - Drug Profile
Recombinant Proteins for Pseudomonas aeruginosa Infection - Drug Profile
RX-05 - Drug Profile
RXP-763 - Drug Profile
RXP-766 - Drug Profile
RXP-770 - Drug Profile
RXP-792 - Drug Profile
RXP-793 - Drug Profile
RXP-808 - Drug Profile
RXP-873 - Drug Profile
S-649266 - Drug Profile
SLP-0901 - Drug Profile
Small Molecule 2 to Inhibit Lectin B for Pseudomonas Aeruginosa Infections - Drug Profile
Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile
Small Molecule to Inhibit Lectins for Pseudomonas Infections - Drug Profile
Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile
Small Molecules for Bacterial Infections - Drug Profile
Small Molecules for Gram-Negative Bacterial Infections - Drug Profile
Small Molecules for Gram-Negative Bacterial Infections and Pseudomonas Aeruginosa Infections - Drug Profile
Small Molecules for Multi-Drug Resistant Bacterial Infections - Drug Profile
Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile
Small Molecules for Resistant Pseudomonas aeruginosa Infections - Drug Profile
Small Molecules to Inhibit LasB for Pseudomonas Aeruginosa Infections - Drug Profile
Small Molecules to Inhibit LasR Receptor for Lung Infections and Pseudomonas aeruginosa Infections - Drug Profile
Small Molecules to Inhibit Lectin B for Pseudomonas Aeruginosa Infections - Drug Profile
Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile
Small Molecules to Inhibit MvfR for Pseudomonas aeruginosa Infections - Drug Profile
Small Molecules to Inhibit PqsD for Pseudomonas Aeruginosa Infections - Drug Profile
Small Molecules to Inhibit T3SS for Pseudomonas Aeruginosa Infections - Drug Profile
Small Molecules to Inhibit the Fatty Acid Synthesis for Pseudomonas Aeruginosa Infections - Drug Profile
Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile
Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile
TP-433 - Drug Profile
TP-559 - Drug Profile
TP-6076 - Drug Profile
V-2L2MD - Drug Profile
VAR-10100 - Drug Profile
VLA-43 - Drug Profile
VXD-002 - Drug Profile
ZP-044 - Drug Profile
ZP-046 - Drug Profile
Pseudomonas Aeruginosa Infections - Recent Pipeline Updates
Pseudomonas Aeruginosa Infections - Dormant Projects
Pseudomonas Aeruginosa Infections - Discontinued Products
Pseudomonas Aeruginosa Infections - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Pseudomonas Aeruginosa Infections, H2 2015
Number of Products under Development for Pseudomonas Aeruginosa Infections - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Achaogen Inc., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Adenium Biotech ApS, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by AlgiPharma AS, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by AmpliPhi Biosciences Corporation, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by AnGes MG, Inc., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Arch Biopartners, Inc., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Arno Therapeutics, Inc., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by AstraZeneca Plc, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Biolytics Pharma, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by CSA Biotechnologies LLC , H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Evaxion Biotech, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by FOB Synthesis, Inc., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by GlaxoSmithKline Plc, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by GlycoMimetics, Inc., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Helix BioMedix, Inc., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Hsiri Therapeutics, LLC, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Insmed Incorporated, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Lascco SA, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by LegoChem Biosciences, Inc, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Lytix Biopharma AS, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by MedImmune, LLC, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Melinta Therapeutics, Inc, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Microbiotix, Inc., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Nosopharm SAS, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Novabiotics Limited, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Novan, Inc., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Omnia Molecular Ltd., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Pfizer Inc., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Pherecydes Pharma SA, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Phico Therapeutics Limited, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Phylogica Limited, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Polyphor Ltd., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Sanofi, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Sealife PHARMA GMBH, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Sequoia Sciences, Inc., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Shionogi & Co., Ltd., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Soligenix, Inc., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Syntiron LLC, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Trana Discovery, Inc., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Valneva SE, H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Varinel, Inc., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Vaxdyn, S.L., H2 2015
Pseudomonas Aeruginosa Infections - Pipeline by Zambon Company S.p.A., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Pseudomonas Aeruginosa Infections Therapeutics - Recent Pipeline Updates, H2 2015
Pseudomonas Aeruginosa Infections - Dormant Projects, H2 2015
Pseudomonas Aeruginosa Infections - Dormant Projects (Contd..1), H2 2015
Pseudomonas Aeruginosa Infections - Dormant Projects (Contd..2), H2 2015
Pseudomonas Aeruginosa Infections - Dormant Projects (Contd..3), H2 2015
Pseudomonas Aeruginosa Infections - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Pseudomonas Aeruginosa Infections, H2 2015
Number of Products under Development for Pseudomonas Aeruginosa Infections - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report